Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Ya’an Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2076-3692; OpenAlex author ID A5054388259. Sources: OpenAlex.

Their work

Papers
57 (first author 4, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
185
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 5 papers · 2015: 3 papers · 2016: 6 papers · 2017: 8 papers · 2018: 7 papers · 2019: 9 papers · 2020: 1 paper · 2021: 6 papers · 2022: 3 papers · 2023: none · 2024: 4 papers · 2025: none · 2026: 2 papers

Papers 50 of 57

  1. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  2. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  3. Retraction Note: Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarci… Co-author DOI 10.1038/s41418-024-01387-2↗
  4. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  5. Editor's Note: Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-1527↗
  6. MiR-21-mediated Metabolic Alteration of Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer Cell Behavior: Retraction. Last author DOI 10.7150/ijbs.91613↗
  7. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  8. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  9. Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells. Last author DOI 10.3892/ol.2022.13227↗
  10. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Co-author DOI 10.1016/j.canlet.2020.12.008↗
  11. Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Co-author DOI 10.1038/s41419-021-03970-8↗
  12. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Co-author DOI 10.1038/s43018-021-00268-8↗
  13. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-20-3792↗
  14. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-20-1228↗
  15. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. First author DOI 10.1172/jci.insight.146133↗
  16. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗
  17. Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signa… Co-author DOI 10.1002/cam4.2581↗
  18. Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide. Co-author DOI 10.1007/s10544-019-0375-z↗
  19. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models. Co-author DOI 10.1016/j.sopen.2019.05.004↗
  20. Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer. Co-author DOI 10.1021/acs.jproteome.9b00132↗
  21. Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-018-0207-3↗
  22. Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor. Co-author DOI 10.1039/c9sc00283a↗
  23. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-0187↗
  24. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. Co-author DOI 10.1172/jci.insight.126915↗
  25. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.130811↗
  26. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.biomaterials.2018.01.014↗
  27. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
  28. SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Co-author DOI 10.1158/1078-0432.ccr-17-3435↗
  29. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  30. Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism Co-author DOI 10.2139/ssrn.3188491↗
  31. Conversion of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition is mediated by oxygen concentration in pancreatic cancer cells. Last author DOI 10.3892/ol.2018.8219↗
  32. MiR-21-mediated Metabolic Alteration of Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer Cell Behavior. Last author DOI 10.7150/ijbs.22555↗
  33. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.06.026↗
  34. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
  35. Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth. First author DOI 10.1038/onc.2017.125↗
  36. MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway. Co-author DOI 10.1080/15548627.2017.1280217↗
  37. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗
  38. Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarci… Co-author DOI 10.1158/1535-7163.mct-16-0526↗
  39. Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. Last author DOI 10.3892/ijo.2016.3779↗
  40. Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism. Last author DOI 10.3892/or.2017.5479↗
  41. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.05.063↗
  42. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2016.09.003↗
  43. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition. Co-author DOI 10.1038/onc.2016.20↗
  44. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Co-author DOI 10.1158/0008-5472.can-16-0715↗
  45. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1078-0432.ccr-15-2780↗
  46. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-15-2936↗
  47. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Co-author DOI 10.1038/labinvest.2014.143↗
  48. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adeno… Co-author DOI 10.1245/s10434-014-4241-1↗
  49. Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0121082↗
  50. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗

Closest collaborators

The 25 strongest of 185 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jason B. Fleming · 50 shared papers, 2012–2026 · strength 4.08
  2. Huamin Wang · 23 shared papers, 2012–2026 · strength 1.68
  3. Anirban Maitra · 18 shared papers, 2014–2026 · strength 1.48
  4. Xinqun Li · 13 shared papers, 2014–2024 · strength 1.35
  5. Michael P. Kim · 15 shared papers, 2012–2024 · strength 1.33
  6. Eugene Jon Koay · 16 shared papers, 2014–2024 · strength 1.28
  7. Bingbing Dai · 13 shared papers, 2016–2024 · strength 1.26
  8. Mayrim V. Rios Perez · 12 shared papers, 2016–2024 · strength 1.20
  9. David Roife · 13 shared papers, 2014–2024 · strength 1.09
  10. Matthew H. G. Katz · 13 shared papers, 2014–2022 · strength 0.86
  11. Haoqiang Ying · 9 shared papers, 2013–2026 · strength 0.83
  12. Tao Shan · 6 shared papers, 2017–2024 · strength 0.68
  13. Ronald Anthony Depinho · 7 shared papers, 2013–2026 · strength 0.67
  14. Giulio Francesco Draetta · 7 shared papers, 2014–2026 · strength 0.67
  15. Timothy Paul Heffernan · 7 shared papers, 2014–2026 · strength 0.59
  16. Andrea Viale · 5 shared papers, 2014–2026 · strength 0.53
  17. Giannicola Genovese · 5 shared papers, 2014–2026 · strength 0.53
  18. Paul J. Chiao · 6 shared papers, 2012–2024 · strength 0.52
  19. Rolf A. Brekken · 4 shared papers, 2017–2024 · strength 0.49
  20. Yeon‐Ju Lee · 5 shared papers, 2016–2024 · strength 0.46
  21. Jenying Deng · 4 shared papers, 2021–2022 · strength 0.45
  22. Alessandro Carugo · 5 shared papers, 2014–2026 · strength 0.44
  23. Wantong Yao · 5 shared papers, 2014–2026 · strength 0.44
  24. Shuo Chen · 3 shared papers, 2017–2024 · strength 0.40
  25. Jun Yao · 4 shared papers, 2018–2024 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.